{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041200","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.150314+00:00","generated_at":"2026-06-04T05:18:08.156927+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Iovance Biotherapeutics director McPeak to retire; interim CEO Vogt nominated to board","bullets":["Director Merrill A. McPeak to retire and not stand for re-election at June 2024 annual meeting.","Frederick G. Vogt, Interim CEO and General Counsel, nominated to fill the vacancy.","Board unanimously adopted Fourth Amended and Restated Bylaws redefining 'Acting in Concert'.","McPeak's retirement is not due to any disagreement with the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041200","json":"https://secwatch.observer/filing/0001104659-24-041200.json","markdown":"https://secwatch.observer/filing/0001104659-24-041200.md","text":"https://secwatch.observer/filing/0001104659-24-041200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/0001104659-24-041200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/tm2410183d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:18:08.156927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"911f4eb98d","claim":"Frederick G. Vogt was appointed as Director at IOVANCE BIOTHERAPEUTICS, INC..","evidence_excerpt":"Frederick G. Vogt, Ph.D., J.D., the Company’s Interim Chief Executive Officer and President, and General Counsel, be nominated to stand for election to the Board at the Annual Meeting","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/0001104659-24-041200-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"nominated to stand for election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e93b94e189","claim":"Merrill A. McPeak retired as Director at IOVANCE BIOTHERAPEUTICS, INC..","evidence_excerpt":"General (Ret.) Merrill A. McPeak, a member of the Board of Directors (the “ Board ”) of Iovance Biotherapeutics, Inc. (the “ Company ”), provided notice to the Board that he will retire and not be standing for re-election to the Board at the Company’s annual meeting","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/0001104659-24-041200-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c4f42366efa767823cb0c99ee652e119a6301d7a","claim":"IOVANCE BIOTHERAPEUTICS, INC.: Amended and restated bylaws to modify the definition of 'Acting in Concert' (effective 2024-03-28).","evidence_excerpt":"On March 28, 2024, the Board unanimously adopted the Company’s Fourth Amended and Restated Bylaws","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/0001104659-24-041200-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-03-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}